Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b open-label extension of adalimumab 100 mg/mL in rheumatoid arthritis (M13-390 completers)
2012-003881-42Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adalimumab in rheumatoid arthritis (RA), sponsored by AbbVie Inc. Started Dec 2012; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-003881-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003881-42.